Page last updated: 2024-12-05
dimethylsilanediol
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 14014 |
| CHEBI ID | 23816 |
| MeSH ID | M0368736 |
Synonyms (22)
| Synonym |
|---|
| unii-dnz4kje28u |
| silanediol, 1,1-dimethyl- |
| einecs 213-915-7 |
| dnz4kje28u , |
| silanediol, dimethyl- |
| CHEBI:23816 |
| dimethylsilanediol |
| (ch3)2si(oh)2 |
| 1066-42-8 |
| si(oh)2me2 |
| dihydroxy(dimethyl)silane |
| DTXSID2061434 |
| dihydroxydimethylsilane |
| XCLIHDJZGPCUBT-UHFFFAOYSA-N |
| dimethylsilanediol # |
| 31692-79-2 |
| 1,1-dimethylsilanediol |
| Q1225753 |
| A934210 |
| polydimethylsiloxane, hydroxy terminated, m.w. 4200 |
| poly(dimethylsiloxane) hydroxy terminated |
| F71313 |
Research Excerpts
Overview
Dimethylsilanediol is a stable crystalline solid that was described in 1953.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Dimethylsilanediol is a stable crystalline solid that was described in 1953. " | ( Hydrophobization of inorganic oxide surfaces using dimethylsilanediol. Krumpfer, JW; Lin, Y; McCarthy, TJ; Wang, L; Watkins, JJ, 2013) | 2.08 |
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " The Cosmetic Ingredient Review (CIR) Expert Panel reviewed relevant data and concluded that these ingredients are safe in the present practices of use and concentration described in this safety assessment." | ( Safety Assessment of Dimethiconol and Its Esters and Reaction Products as Used in Cosmetics. Andersen, FA; Belsito, DV; Bergfeld, WF; Heldreth, B; Hill, RA; Johnson, W; Klaassen, CD; Liebler, DC; Marks, JG; Shank, RC; Slaga, TJ; Snyder, PW, ) | 0.13 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "Removing volatile methyl siloxanes (VMSs) from biogas remains a longstanding challenge in the field of biological process due to their low bioavailability and biodegradation." | ( Siloxanes removal from biogas by a lab-scale biotrickling filter inoculated with Pseudomonas aeruginosa S240. Li, Y; Xu, J; Zhang, W, 2014) | 0.4 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| organosilanediol | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 37.37
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (37.37) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||